Hepatocarcinogenesis in transgenic mice carrying hepatitis C virus cDNA
Hepatocarcinogenesis in transgenic mice carrying hepatitis C virus cDNA
批准号:
11470061
负责人:
ESUMI Mariko
金额:
$8.58万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (B)
财政年份:
1999
资助国家:
日本
项目状态:
已结题
起止时间:
1999 至 2001
中文摘要
点击翻译按钮获取中文摘要
英文摘要
1 Expression analysis of transgenic miceWe analyzed 5 lines of transgenic mice carrying the whole genome of hepatitis C virus (HCV); A44, A39 and A48 were controlled under the mouse albumin enhancer/ promoter; S2 and S5 were under the SR_α promoter. The HCV mRNA was expressed in the liver of one of 17 A44 at the age of 12 months and 12 of 17 A44 at the age of 21 months. All mice of A39 and A48 expressed the HCV transgene in the liver, but both S2 and S5 did not. The mRNA was 9.4 kb in length, and the real-time PCR revealed that 50 to 4000 copies of HCV RNA were expressed in 1 μg of total RNA. The expression of HCV mRNA seemed to be localized in the liver tissue. Less than the detection limit of HCV core protein (5 pg/mg protein) was detected in the liver. These transgenic mice A39, A44 and A48 showed the similar level of HCV expression to that of patients with chronic hepatitis C, that is different from other transgenic mice with the high level of HCV expression.2 Histological examinat … More ion of transgenic mouse liverInflammatory cell infiltration and spotty necrosis were observed in transgenic mouse liver of A39, A44 and A48. The number of spotty necrosis foci was significantly higher in A39 and A44 than non-transgenic mice at the age of 21 months. The fatty change of liver was not significant between transgenics and non-transgenics. Liver fibrosis and tumorous lesion were not observed until 21 months old. HCV antibodies were not detected in serum of the mice.3 Molecular pathogenesis of transgenic mouse liverReal-time RT-PCR of mRNA revealed that mRNAs such as interferon-inducible genes and cell cycle-related genes were up-regulated in transgenic mouse liver, that is observed in patients with HCV infection.Thus, these transgenic mice were similar to patients with weak hepatitis. Anti-viral immune response of the mice, however, was so much less than that of patients, suggesting that the introduction of anti-viral immune system to these HCV transgenic mice should be required for establishing a model of hepatocarcinogenesis. Less
期刊论文(72)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Zhou Y, et al.(2): "Multiple sequence-reactive antibodies induced by a single peptide immunization with hypervariable region 1 of hepatitis C virus"Virology. 262. 360-370 (1999)
Zhou Y等人(2):“丙型肝炎病毒高变区1单肽免疫诱导的多重序列反应性抗体”病毒学。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Esumi M, et al.(4): "In vivo and in vitro evidence that cross-reactive antibodies to C-terminus of hypervariable region 1 do not neutralize heterologous hepatitis C virus"Vaccine. 20. 3095-3103 (2002)
Esumi M 等人 (4):“体内和体外证据表明,高变区 1 C 末端的交叉反应抗体不会中和异源丙型肝炎病毒”疫苗。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Iwasaki Y, Esumi M., Hosokawa N., Yanai M. and Kawano K.: "Occasional infection of hepatitis C virus occurring in haemodialysis units identified by serial monitoring of the virus infection"J. Hosp. Infect.. 45(1). 54-61 (2000)
Iwasaki Y、Esumi M.、Hosokawa N.、Yanai M. 和 Kawano K.:“通过对病毒感染的系列监测发现血液透析单位偶尔发生丙型肝炎病毒感染”J.
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Esumi M, et al.(6): "Experimental vaccine activities of recombinant E1 and E2 glycoproteins and hypervariable region 1 peptides of hepatitis C virus in chimpanzees"Archives of Virology. 144. 973-980 (1999)
Esumi M等人(6):“丙型肝炎病毒重组E1和E2糖蛋白和高变区1肽在黑猩猩中的实验疫苗活性”病毒学档案。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Iwasaki Y, et al.(4): "Occasional infection of hepatitis C virus occurring in haemodialysis units identified by serial monitoring of the virus infection"Journal of Hospital Infection. 45. 54-61 (2000)
Iwasaki Y 等人 (4):“通过病毒感染的系列监测发现血液透析单位偶发丙型肝炎病毒感染”《医院感染杂志》。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
共 35 条
Precancerous signatures explored through micro-genomics and micro-proteomics
-
批准号:25430142
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$3.41万
-
财政年份:2013
-
负责人:ESUMI Mariko
-
依托单位:
Cellular and microenvironmental factors controlling hepatitis Cvirus infection, examined by micro-proteomics of human liver tissues.
-
批准号:22590350
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.91万
-
财政年份:2010
-
负责人:ESUMI Mariko
-
依托单位:
Development of animal models with hepatitis C and hepatocellular carcinoma by transgenic techniques
-
批准号:08457077
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$4.35万
-
财政年份:1996
-
负责人:ESUMI Mariko
-
依托单位:
cDNA cloning of Fab fragment against hepatitis C virus to produce humanized monoclonal antibody
-
批准号:05454185
-
项目类别:Grant-in-Aid for General Scientific Research (B)
-
资助金额:$4.1万
-
财政年份:1993
-
负责人:ESUMI Mariko
-
依托单位:
海外基金